| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 3,000 | 19,640 | 3,850 | 1,570 | 2,970 |
| Sales Growth | -84.73% | +410.13% | +145.22% | -47.14% | +26.92% |
| Net Income | -20,190 | -16,630 | -12,880 | -7,450 | -102,260 |
| Net Income Growth | -21.41% | -29.11% | -72.89% | +92.71% | -27.19% |
Atrium Therapeutics Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Atrium Therapeutics Inc. is pioneering targeted delivery of ribonucleic acid therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The company's pipeline consists of precision cardiology candidates, ATR 1072 and ATR 1086. Atrium Therapeutics Inc. is based in SAN DIEGO.
Fiscal Year End Date: 12/31